Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaemoneticsFRA:HAZ 84 EBITDA Margin % is 24.92% as of Jun. 2026, which is 25% above its 10-year median of 20.01. GuruFocus rates FRA:HAZ with a GF Score™ of 84/100 and a GF Value™ of €73.15 (Fairly Valued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Haemonetics ranks better than 74.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Haemonetics's EBITDA for the
three
months ended in Jun. 2026 was €73 Mil. Haemonetics's Revenue for the
three
months ended in Jun. 2026 was €295 Mil. Therefore, Haemonetics's EBITDA margin for the quarter that ended in Jun. 2026 was 24.92%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Haemonetics EBITDA Margin % Related Terms
Haemonetics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Haemonetics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HAZ vs IRTC, ITGR, LIVN: EBITDA Margin % Comparison
For the Medical Devices subindustry, Haemonetics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Haemonetics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics (FRA:HAZ) has a EBITDA Margin % of 24.92% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haemonetics and its competitors. This is 25% above median its historical median of 20.01. Over the past decade, Haemonetics' EBITDA Margin % has ranged from 7.94 to 24.79. According to the industry distribution chart, Haemonetics ranks #206 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 25.2%.
Is Haemonetics' EBITDA Margin % too high?
Haemonetics' current EBITDA Margin % of 24.92% is 25% above median its 10-year median of 20.01. Over the past 10 years, this metric has ranged from a low of 7.94 to a high of 24.79. The Medical Devices & Instruments industry median EBITDA Margin % is 7.63. Haemonetics' value of 24.92% is 226.8% above this industry median. Based on the distribution chart, Haemonetics ranks #206 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Haemonetics has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' EBITDA Margin % compare to IRTC and ITGR?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #206 out of 816 companies for EBITDA Margin %. This puts Haemonetics in the upper half of its industry. The industry median EBITDA Margin % is 7.63. Haemonetics' value of 24.92% is 226.8% above this benchmark. Historically, Haemonetics' own EBITDA Margin % has ranged from 7.94 to 24.79 over the past decade. While the company's 10-year median is 20.01 vs. the industry median of 7.63, Haemonetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.63, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haemonetics's current EBITDA Margin % of 24.92% is 226.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haemonetics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current EBITDA Margin % is 24.92%, which is 25% above median its own 10-year median of 20.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (FRA:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €73.15, compared to a current price of €78.00 — trading 6.6% above its estimated fair value. The current EBITDA Margin % is 24.92%, which is 25% above median its 10-year median of 20.01 and 226.8% above the Medical Devices & Instruments industry median of 7.63. Haemonetics' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Haemonetics (FRA:HAZ), the current EBITDA Margin % is 24.92% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haemonetics (FRA:HAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued.
The current stock price of €78.00 is trading 6.6% above its estimated GF Value™ of €73.15.
GuruFocus considers Haemonetics to be Fairly Valued.
Key valuation signals for FRA:HAZ:
EBITDA Margin %: 24.92% (25% above median its 10-year median of 20.01)
GF Value™: €73.15 vs. price of €78.00 (6.6% above fair value)
Industry Position: 226.8% above the Medical Devices & Instruments median (#206 of 816)
No single metric tells the full story. See the FRA:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
84GF Score
Get the complete analysis for FRA:HAZ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HAZ has been successfully added to your 
